GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on February 17, 2026, reports the vesting of Performance Share Plan (PSP) awards granted in February 2023 to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The three-year performance period covered January 1, 2023, through December 31, 2025, with awards vesting on February 13, 2026.
Key Financial Metrics and Performance Outcomes
The filing details the performance metrics used to determine the vesting percentage for the 2023 PSP awards. The overall vesting level for the cohort was 82%, with 18% of the awards lapsing.
| Performance Measure | Weight | Outcome | Vesting Level |
|---|---|---|---|
| Total Shareholder Return (TSR) | 30% | Ranked 5th out of 10 comparator companies | 40% of maximum |
| Total Sales | 20% | £99.03bn achieved (Target: £94.58bn) | 100% of maximum |
| Total Profit | 20% | £30.22bn achieved (Target: £29.43bn) | 100% of maximum |
| Pipeline Progress | 20% | Pivotal trial starts and regulatory approvals met | 100% of maximum |
| Responsible Business (Environment) | 10% | Nature Net Positive and Climate Net Zero goals met/exceeded ahead of 2030 target | 100% of maximum |
Market Data: On the vesting date (February 13, 2026), the closing price for GSK Ordinary Shares was £21.65 and American Depositary Shares (ADS) were $58.93.
Material Changes and Transactions
The filing documents specific transactions for 14 PDMRs/PCAs, including CEO Luke Miels and other senior executives. For each individual, two transactions were recorded:
- Vesting: Receipt of Ordinary Shares or ADS at a price of £0.00 or $0.00.
- Tax Sale: Immediate sale of a portion of the vested shares to meet tax liabilities.
Sales were executed on the London Stock Exchange (XLON) at approximately £21.60 per share or the New York Stock Exchange (XNYS) at approximately $58.85 per ADS.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the standard disclosure of performance conditions. The document confirms that the company met or exceeded its environmental targets for Nature Net Positive and Climate Net Zero impact ahead of the 2030 deadline.
Key Facts for Investor Verification
- Performance Success: GSK exceeded targets for Total Sales (£99.03bn vs £94.58bn) and Total Profit (£30.22bn vs £29.43bn) for the 2023-2025 period.
- TSR Underperformance: The Total Shareholder Return metric resulted in only 40% vesting, indicating the company ranked 5th among peers, which dragged down the overall vesting percentage to 82%.
- Executive Retention: The vesting of awards for key executives (including the CEO, Chief Scientific Officer, and regional presidents) suggests continued alignment with company performance goals.
- ESG Achievement: The company achieved maximum vesting for environmental criteria, meeting 2030 targets early.
- Transaction Volume: Significant share volumes were vested and subsequently sold for tax purposes by senior management on February 13, 2026.